ArticleNature communications2026
Mapping glioblastoma's isoform diversity using long-read single-cell analysis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is a highly aggressive brain tumor with poor prognosis, partly driven by extensive intratumoral heterogeneity and widespread dysregulation of RNA splicing. Alternative splicing shapes cellular identity and function and contributes to tumor progression and treatment resistance. While single-cell RNA sequencing has revealed diverse cellular states within glioblastoma, conventional short-read approaches cannot resolve full-length isoforms. Here, we apply single-cell long-read RNA sequencing to construct an isoform-level atlas of glioblastoma. By capturing full-length transcripts at single-cell resolution, hundreds of isoforms with differential transcript usage across distinct tumor cell populations are identified. We develop a framework to prioritize tumor-restricted isoforms and identify surface-intracellular target pairs in seven patients, suggesting opportunities for dual-specific ligand-based therapies. Furthermore, 6524 isoforms absent from existing annotations are discovered, including 179 that are tumor-specific. Peptides derived from these isoforms show strong predicted binding to major histocompatibility complex class I molecules, highlighting their potential as neoantigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.